Dianthus Therapeutics, Inc.DNTHEarnings & Financial Report
Dianthus Therapeutics is a clinical-stage biopharmaceutical firm focused on developing targeted therapies for rare immunological and inflammatory diseases. It advances antibody-based candidates to address unmet needs of severe patients, operating primarily in the U.S. with global development partners.
Revenue
$1.9M
Gross Profit
N/A
Operating Profit
$-22.2M
Net Profit
$-17.6M
Gross Margin
N/A
Operating Margin
-1191.8%
Net Margin
-945.1%
YoY Growth
N/A
EPS
$-0.51
Dianthus Therapeutics, Inc. Q2 FY2024 Financial Summary
Dianthus Therapeutics, Inc. reported revenue of $1.9M for Q2 FY2024, with a net profit of $-17.6M (down 58.1% YoY) (-945.1% margin).
Key Financial Metrics
| Total Revenue | $1.9M |
|---|---|
| Net Profit | $-17.6M |
| Gross Margin | N/A |
| Operating Margin | -1191.8% |
| Report Period | Q2 FY2024 |
Dianthus Therapeutics, Inc. Annual Revenue by Year
Dianthus Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $6.2M).
| Year | Annual Revenue |
|---|---|
| 2024 | $6.2M |
Dianthus Therapeutics, Inc. Quarterly Revenue & Net Profit History
Dianthus Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $284.0K | -78.6% | $-64.4M | -22687.3% |
| Q3 FY2025 | $396.0K | -81.8% | $-36.8M | -9284.1% |
| Q1 FY2025 | $1.2M | +33.1% | $-29.5M | -2537.5% |
| Q4 FY2024 | $1.3M | — | $-28.4M | -2144.8% |
| Q3 FY2024 | $2.2M | +135.1% | $-25.2M | -1159.0% |
| Q2 FY2024 | $1.9M | — | $-17.6M | -945.1% |
| Q1 FY2024 | $874.0K | — | $-13.7M | -1573.0% |
| Q3 FY2023 | $924.0K | -21.2% | $-14.8M | -1597.7% |
Income Statement
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $924000 | $874000 | $1.9M | $2.2M | $1.3M | $1.2M | $396000 | $284000 |
| YoY Growth | -21.2% | N/A | N/A | 135.1% | N/A | 33.1% | -81.8% | -78.6% |
Balance Sheet
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $192.5M | $382.5M | $369.0M | $354.2M | $374.0M | $348.6M | $577.4M | $530.9M |
| Liabilities | $14.1M | $9.8M | $10.7M | $16.4M | $21.5M | $20.0M | $31.0M | $37.5M |
| Equity | $178.4M | $372.7M | $358.2M | $337.9M | $352.5M | $328.6M | $546.5M | $493.4M |
Cash Flow
| Q3 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.0M | $-14.9M | $-14.5M | $-21.3M | $-27.4M | $-27.6M | $-30.6M | $-47.0M |